Research
Molecular
Recently completed and ongoing trials of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors will inform clinical practice on safe and effective ways to reduce cardiovascular risk in T2DM.
Healthcare providers should stay updated on findings from these trials to optimize T2DM treatment strategies.
StrongSupportsmedium confidence
Recently completed and ongoing trials of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors will continue to inform clinical practice on safe and effective ways to reduce CV risk in T2DM.
Why this rating
The mention of ongoing trials indicates a robust evidence base.
Source
Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
Karan Kapoor et al. · Cardiology · 2016
DOI 10.1159/000446471
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The post-ACCORD era represents a significant shift in the landscape of cardiovascular outcomes trials (CVOTs) in type 2 diabetes mellitus (T2DM), emphasizing the safety of glucose-lowering agents.Strong
- Heterogeneous results were observed regarding the degree of glycemic control associated with optimal macrovascular disease risk reduction.Strong
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →